Show simple item record

dc.contributor.authorMooranian, A.
dc.contributor.authorNegrulj, R.
dc.contributor.authorMorahan, G.
dc.contributor.authorJamieson, E.
dc.contributor.authorAl-Salami, Hani
dc.date.accessioned2017-01-30T14:41:08Z
dc.date.available2017-01-30T14:41:08Z
dc.date.created2016-01-18T20:00:39Z
dc.date.issued2016
dc.identifier.citationMooranian, A. and Negrulj, R. and Morahan, G. and Jamieson, E. and Al-Salami, H. 2016. Designing anti-diabetic ß-cells microcapsules using polystyrenic sulfonate, polyallylamine and a tertiary bile acid: Morphology, bioenergetics and cytokine analysis. Biotechnology Progress. 32 (2): pp. 501-509.
dc.identifier.urihttp://hdl.handle.net/20.500.11937/40271
dc.identifier.doi10.1002/btpr.2223
dc.description.abstract

Purpose: Recently sodium alginate (SA)-poly-l-ornithine (PLO) microcapsules containing pancreatic β-cells that showed good morphology but low cell viability (<27%) was designed. In this study, two new polyelectrolytes, polystyrenic sulfonate (PSS; at 1%) and polyallylamine (PAA; at 2%) were incorporated into a microencapsulated-formulation, with the aim of enhancing the physical properties of the microcapsules. Following incorporation, the structural characteristics and cell viability were investigated. The effects of the anti-inflammatory bile acid, ursodeoxycholic acid (UDCA), on microcapsule morphology, size, and stability as well as β-cell biological functionality was also examined. Methods: Microcapsules were prepared using PLO-PSS-PAA-SA mixture and two types of microcapsules were produced: without UDCA (control) and with UDCA (test). Microcapsule morphology, stability, and size were examined. Cell count, microencapsulation efficiency, cell bioenergetics, and activity were also examined. Results: The new microcapsules showed good morphology but cell viability remained low (29% ± 3%).UDCA addition improved cell viability post-microencapsulation (42 ± 5, P < 0.01), reduced swelling (P < 0.01), improved mechanical strength (P < 0.01), increased Zeta-potential (P < 0.01), and improved stability. UDCA addition also increased insulin production (P < 0.01), bioenergetics (P < 0.01), and decreased β-cell TNF-α (P < 0.01), IFN-gamma (P < 0.01), and IL-6 (P < 0.01) secretions. Conclusions: Addition of 4% UDCA to a formulation system consisting of 1.8% SA, 1% PLO, 1% PSS, and 2% PAA enhanced cell viability post-microencapsulation and resulted in a more stable formulation with enhanced encapsulated β-cell metabolism, bioenergetics, and biological activity with reduced inflammation. This suggests potential application of UDCA, when combined with SA, PLO, PSS, and PAA, in β-cell microencapsulation and diabetes treatment.

dc.titleDesigning anti-diabetic ß-cells microcapsules using polystyrenic sulfonate, polyallylamine and a tertiary bile acid: Morphology, bioenergetics and cytokine analysis.
dc.typeJournal Article
dcterms.source.titleBiotechnol Prog
curtin.departmentSchool of Pharmacy
curtin.accessStatusFulltext not available


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record